Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ASP-1929 |
Synonyms | |
Therapy Description |
ASP1929 (RM-1929) is comprised of the EGFR antibody cetuximab conjugated to the dye IR700, which binds to EGFR-expressing cells and disrupts the cell membrane upon exposure to near-infared light (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASP-1929 | Cetuximab sarotalocan|Cetuximab-IRDye-700DX|RM-1929|Cet-IR700|ASP1929 | EGFR Antibody 43 | ASP1929 (RM-1929) is comprised of the EGFR antibody cetuximab conjugated to the dye IR700, which binds to EGFR-expressing cells and disrupts the cell membrane upon exposure to near-infared light (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02422979 | Phase I | ASP-1929 | Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer | Completed | USA | 0 |
NCT03769506 | Phase III | Methotrexate Cetuximab ASP-1929 Docetaxel Paclitaxel | ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy | Recruiting | USA | ESP | BEL | 3 |